Evaluation of VEGF, VEGFR 1-2-3 and Endocan/ESM-1 Expression in Gastroenteropancreatic Neuroendocrine Tumors and Correlation with Ki-67 Labeling and Prognosis Abstract #756

Introduction: Angiogenesis is recognized to play a critical role in progressive tumor growth and spreading and its inhibition is a valuable approach to cancer treatment. Markers of angiogenesis include assessment of microvessel density on tissue sections (often evaluated with antibodies against pan-endothelial antigens, such as CD34) and expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFR 1-2-3). Endocan, also called endothelial cell specific molecule-1 (ESM-1), has been shown to be expressed by endothelial tumor cells and especially by tip cells during angiogenesis. Endocan is highly up-regulated by pro-angiogenic molecules, such as VEGF. Recently, Endocan has been identified to be one of the molecules involved in the switch from dormant to fast-growing tumors. Among endocrine tumors, Endocan expression has been evaluated only in pituitary adenomas: a positive association between endothelial Endocan expression and recurrence risk, tumor size, tumoral invasion and average mitosis count has been demonstrated. In contrast, there was no association between endothelial Endocan expression and the Ki-67 labeling index
Aim(s):
Materials and methods: Assessment of immunohistochemical VEGF, VEGFR 1-2-3 and Endocan expression in a series of GEP NETs and comparison of these markers with clinical features, Ki-67 labeling, TNM staging and PFS to assess their prognostic value.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Laura De Marinis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#299 Clinical and Immunohistochemical Evaluation of Medullary Thyroid Cancer (MTC) and C Cell Hyperplasia (CCH)
Introduction: MTC and CCH has a variable clinical presentation and prognosis and no data are available on the correlation between immunoistochemical (IIC) characterization and clinical behavior.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Prof Laura De Marinis
Authors: Lugli F, Fusco A, Bianchi A, Milardi D, ...
#1013 Evaluation of VEGF and Endocan/ESM-1 Expression in pNETs and Correlation with Ki-67 and Prognosis
Introduction: Endocan has been reported as specific of endothelial tumor cells and was shown to be expressed by tip cells during the angiogenesis process.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Laura De Marinis
Authors: Lugli F, Iacovazzo D, Lanza P, Inzani F, ...
Keywords: GEP-NET, Endocan, VEGF
#1374 The Usefulness of Assessment the Serum Concentrations of Vascular Endothelial Growth Factor (VEGF) and Its Soluble Receptor Type 2 (VEGFR2) in Patients with Neuroendocrine Neoplasm (NEN)
Introduction: Angiogenesis plays an important role in tumour growth and disease progression. VEGF is a angiogenesis-stimulating factor. VEGFR2 has antiangiogenic properties.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: MD PhD Violetta Rosiek
#1249 Impact of VEGF and VEGFR Polymorphisms on Neuroendocrine Tumors of the Gastro-Entero-Pancreatic System (GEP-NET) Outcome.
Introduction: Improving our understanding of the molecular biology of GEP-NETs represents a key challenge in the treatment of these rare tumors.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Prof. Rossana Berardi
#77 Angiogenesis markers after hepatic artery embolization of liver metastases in patients with neuroendocrine tumors
Introduction: In the event of diffuse hepatic metastases, hepatic artery embolization (HAE) can be a successful treatment option in patients with well-differentiated neuroendocrine tumors (WNET). Although there are suggestions of activation of the angiogenesis by HAE, no information is available about the development of growth factors caused by vascular obstruction with embolization.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MSc Catharina M Korse
Authors: Korse C M, Bonfrer J M, Taal B G, ...